Axumin® (fluciclovine F 18) is now available at Munson Medical Center for use with PET/CT scans to detect and localize prostate cancer recurrence across local and distant sites.
Munson Medical Center now offers an imaging agent called Axumin that can be administered with a Positron Emission Tomography/Computed Tomography (PET/CT) scan for men with suspected recurrent prostate cancer. PET imaging is much more sensitive and accurate than the use of CT and bone scan for both identification of early recurrence and initial staging of prostate cancer.
Axumin is FDA-approved in the United States for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.1 Axumin can help determine if prostate cancer has spread within the prostate or prostate bed or to other parts of the body.
In a multicenter retrospective study, Axumin detected prostate cancer in 68% of men with elevated PSA (overall detection rate).2 Metastases smaller than 5 mm were detected, and overall detection rates were ~40% at PSA levels ≤0.79 ng/mL, ~60% at PSA 0.8 to 2.03 ng/mL, ~75% at PSA 2.04 to 6.00 ng/mL, and ~85% at PSA ≥6.00 ng/mL.2
For information on how to order an Axumin PET/CT scan, please call the Nuclear Medicine Department at 231-935-7229.
Consider Axumin for your patients with suspected prostate cancer recurrence. To schedule a scan, please contact Radiology Scheduling at 800-968-9292.
Please visit axumin.com to review real-world cases and learn how Axumin PET/CT scans may be able to help inform your treatment decisions.
References:
- Axumin [package insert]. Oxford, UK: Blue Earth Diagnostics Ltd; 2016.
- Bach-Gansmo T, Nanni C, Nieh PT, et al. Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine (18F) positron emission tomography/computerized tomography imaging in the staging of biochemically recurrent prostate cancer. J Urol. 2017;197:676- 683